Malignant Ascites Treatment Market 2021 – Application And Insights, Revenue Forecast, Company Share, Competitive Landscape, Growth Factors and Trends by 2027
SEATTLE, April 01, 2021, (PHARMIWEB) — Global Malignant Ascites Treatment Market
Ascites is the condition characterized by formation of excessive fluid in the abdominal cavity, particularly in the peritoneal cavity. It causes when the body is unable to eliminate out fluids. When ascites is developed due to cancer, it is called as malignant peritoneal effusion or malignant ascites. Malignancies that are most commonly associated with malignant ascites are breast, liver, ovary, lungs, lymphoma, and colon cancers. In ascites condition, lymph glands in the body gets blocked and lead to ascites symptoms including low blood pressure, loss of sleep, fatigue, and skin problems. The key symptoms of malignant ascites include abdominal pain or discomfort, shortness of breath, swelling of the abdomen, leg or ankle swelling, constipation, and weight gain. Diagnosis of ascites can be done by ultrasound, x-ray test, CT scans, and physical examination. The survival rate of these patients is very low, although many suitable treatments, such as paracentesis, chemotherapy, and surgeries, are available. Various conventional treatments for malignant ascites include chemotherapy, shunting, paracentesis, and use of drugs, such as spironolactone and spironolactone. Cirrhosis of the liver is the most common cause of ascites but other conditions such as kidney failure, heart failure, cancer or infection can also cause ascites.
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1775
Global Malignant Ascites Treatment Market – Dynamics
Rising prevalence of cirrhosis is a major factor boosting the growth of the global malignant ascites market. According to a study published in the World Journal of Gastroenterology in 2011, over 50% of patients worldwide develop ascites within ten years of diagnosis. In a published article in the Journal of Clinical and Translational Hepatology, it was highlighted that advancements in the ascites condition is associated with poor prognosis, with a mortality of 15% in one year and around 44% in a five-year follow-up. Moreover, favorable reimbursement policies, such as the 2010 Patient Protection and Affordable Care Act (PPACA), along with increasing incidence of cancer, are propelling the global market growth. For instance, in 2016, NanoAntibiotics acquired LAT Pharma LLC, an early-stage biotechnology company famous for developing new medicines, to treat life-threatening complications of liver cirrhosis.
However, stringent regulations and complications associated with ascites treatment such as internal bleeding after paracentesis treatment, exposure of radiation in chemotherapy may hinder growth of the market over the forecast period. For instance, in the Experimental & Molecular Medicine journal, it was shown that radiation can induce toxicities in non-tumorous liver tissues that may limit the course of therapy or lead to chronic side effects, including late fibrosis.
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://bit.ly/39yyhkG
Global Malignant Ascites Treatment Market – Regional Insights
North America accounts for the largest share in the global malignant ascites treatment market size, owing to high healthcare expenditure, well-developed technology, and increasing prevalence of cirrhosis are accelerating growth of the malignant ascites treatment market in this region. For instance, according to study published in 2015 Journal of Clinical Gastroenterology showed prevalence of cirrhosis in the U.S. was approximately 0.27%, corresponding to 633,323 adults.
Moreover, Asia Pacific is expected to witness significant growth in the market over the forecast period, owing to increasing prevalence of cirrhosis. As per a 2015 study published in the BMJ Open Gastroenterology report, the rate of hospitalization due to viral hepatitis cirrhosis decreased by 10% between 2006 and 2010. However, non-viral hepatitis cirrhosis and alcoholic cirrhosis exhibited an increase of 35% and 33% in China.
Global Malignant Ascites Treatment Market – Competitive Outlook
The key players operating in the global malignant ascites treatment market include PharmaCyte Biotech Inc., Sequana Medical, Fresenius SE & Co. KGaA, BioVie, BD, Medtronic Plc, and GI Supply, Actavis Elizabeth LLC, Mylan Pharmaceuticals Inc., GE Healthcare, Trion Pharma, Siemens AG, and Fresenius Biotech.
To get detailed table of content (ToC), please click – https://www.coherentmarketinsights.com/ongoing-insight/toc/1775
These players are currently adopting a range of strategies, including collaborations, and increasing their R&D funding to strengthen their product portfolios and retain their positions in the global market. For instance, BioVie’s Lead Compound BIV201 received the FDA Orphan-Drug Designation for the treatment of ascites in the year 2016.
Based on treatment type:
- Therapeutic Treatment
- Surgical Treatment
In terms of application:
- Ovarian Cancer
- Breast Cancer
- Gastrointestinal Cancer
- Colorectal Cancer
- Carcinoma of Unknown Primary
- North America
- Latin America
- Asia Pacific
- Middle East
Table of Content
Global Malignant Ascites Treatment Market Research Report
Section 1: Global Malignant Ascites Treatment Industry Overview
Section 2: Global Economic Impact on Malignant Ascites Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Malignant Ascites Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Malignant Ascites Treatment Market Forecast
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire